CDK4 and neoplasm: For patients whose cancers develop resistance to these therapies and who develop locoregional recurrences or metastatic disease, treatment with CDK4/6 inhibitors including palbociclib (4), ribociclib (5), and abemaciclib (6) has demonstrated an increase in progression-free survival time and decreased tumor metastasis (7).